Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

Blood Cancer J. 2024 Oct 14;14(1):178. doi: 10.1038/s41408-024-01148-x.

Authors

Jennifer K Lue¹, Efrat Luttwak², Alfredo Rivas-Delgado², Helen Irawan³, Alexander Boardman², Philip C Caron², Kevin David², Zachary Epstein-Peterson², Lorenzo Falchi², Paola Ghione², Paul Hamlin², Steven M Horwitz², Andrew M Intlekofer², William Johnson², Anita Kumar², Alison Moskowitz², Ariela Noy², M Lia Palomba², Ralphael Steiner², Robert Stuver², Pallawi Torka², Santosha Vardhana², Andrew D Zelenetz², Heiko Schoder⁴, Brandon Imber⁵, Joachim Yahalom⁵, Yanming Zhang³, Pallavi Galera³, Ahmet Dogan³, Umut Aypar³, Gilles Salles²

Affiliations

¹ Lymphoma Service, Division of Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. [email protected].
² Lymphoma Service, Division of Hematological Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁴ Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁵ Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Aged, 80 and over
Female
Gene Rearrangement*
Humans
Lymphoma, B-Cell* / genetics
Lymphoma, B-Cell* / pathology
Male
Middle Aged
Neoplasm Grading
Prognosis
Proto-Oncogene Proteins c-bcl-2* / genetics
Proto-Oncogene Proteins c-bcl-6* / genetics
Proto-Oncogene Proteins c-myc* / genetics

Substances

Proto-Oncogene Proteins c-bcl-6
Proto-Oncogene Proteins c-bcl-2
BCL6 protein, human
Proto-Oncogene Proteins c-myc
BCL2 protein, human
MYC protein, human

Grants and funding